Conclusion
Treatment of SGAH-unresponsive CSU subjects, with benralizumab 30mg
subcutaneously monthly for 3 successive months, versus a placebo dose,
significantly improved disease severity and QoL as measured by UAS7 and
CU-QoL total score, respectively. These observations support the use of
benralizumab for treatment of SGAH unresponsive CSU and provide evidence
for a pathogenic role for infiltrating eosinophils. These data provide
justification for a double-blind, placebo-controlled multicenter study
in a large patient population currently underway.